{
  "abstract": "Objective: To compare the efficacy, survival benefits, and safety of whole-brain radiotherapy (WBRT) alone versus WBRT combined with simultaneous integrated boost (WBRT+SIB) for patients with brain metastases. Methods: A total of 100 patients treated from 2017 to 2022 were retrospectively analyzed. Tumor response was assessed per RECIST 1.1. Survival differences were compared using the Kaplan–Meier method and log-rank test. Multivariate Cox regression and subgroup analyses were performed to evaluate the prognostic value and stability of WBRT+SIB. Results: The WBRT+SIB group exhibited numerically higher objective response and disease control rates without statistical significance. With a median follow-up of 31.0 months, WBRT+SIB significantly prolonged median overall survival (11.0 vs. 8.0 months, p = 0.011) and improved 1-, 2-, and 3-year survival rates. After adjusting for multiple confounders, WBRT+SIB independently reduced mortality risk (HR = 0.51, 95% CI: 0.27–0.97, p = 0.039). Subgroup analyses were exploratory; therefore, consistent survival advantages across strata cannot be confirmed. No significant differences in acute, subacute, or late neurotoxicity, including radiation-induced brain necrosis, were found between the two groups. Conclusions: WBRT+SIB was associated with longer overall survival compared with WBRT alone, without a significant increase in the incidence of radiotherapy-related adverse events. Although ORR and DCR were numerically higher in the WBRT+SIB group, these differences were not statistically significant. Given the limitations of this exploratory study, these findings should be considered hypothesis-generating and require validation in prospective randomized trials.",
  "abstract_shown": true,
  "affiliations": [
    "Department of Radiation Oncology, Shenzhen People’s Hospital (The First Affiliated Hospital, Southern University of Science and Technology, The Second Clinical Medical College, Jinan University), Shenzhen 518020, China"
  ],
  "article_type": null,
  "arxiv": null,
  "author_total": 3,
  "authors": [
    {
      "affs": [
        0
      ],
      "name": "Zibo Tang",
      "orcid": "0000-0002-7526-9464"
    },
    {
      "affs": [
        0
      ],
      "name": "Guixiang Liao",
      "orcid": "0000-0002-4369-8811"
    },
    {
      "affs": [
        0
      ],
      "name": "Juan Fan"
    }
  ],
  "bibtex": "https://research.draconitic.com/paper/75p982e3nnwfd.bib",
  "cited_by": 0,
  "doi": "10.3390/cancers18203320",
  "fulltext_url": null,
  "id": "75p982e3nnwfd",
  "issns": [
    "2072-6694"
  ],
  "landing_url": "https://www.mdpi.com/2072-6694/18/20/3320",
  "language": null,
  "licence": "CC-BY-4.0",
  "licence_label": "CC BY 4.0",
  "licence_source": "article",
  "licence_url": "https://creativecommons.org/licenses/by/4.0/",
  "metadata_licence": null,
  "native_subjects": [
    [
      "openalex",
      "2740|Brain Metastases and Treatment"
    ]
  ],
  "openalex": "W7222161814",
  "pdf_url": null,
  "pmcid": null,
  "pmid": null,
  "published": "2026-10-15",
  "publisher": "MDPI AG",
  "ris": "https://research.draconitic.com/paper/75p982e3nnwfd.ris",
  "sources": [
    {
      "first_seen": "2026-10-30T12:19:58Z",
      "native_id": "10.3390/cancers18203320",
      "source": "crossref",
      "url": "https://www.mdpi.com/2072-6694/18/20/3320"
    }
  ],
  "subjects": [
    {
      "field": "medicine",
      "origin": "issn:2072-6694",
      "subfield": "oncology"
    }
  ],
  "title": "WBRT Plus SIB in Patients with Brain Metastases: Association with Longer Overall Survival and Safety Outcomes in a Single-Center Retrospective Analysis",
  "title_text": "WBRT Plus SIB in Patients with Brain Metastases: Association with Longer Overall Survival and Safety Outcomes in a Single-Center Retrospective Analysis",
  "type": "peer-reviewed",
  "updated_at": "2026-10-30T12:19:58Z",
  "url": "https://research.draconitic.com/paper/75p982e3nnwfd",
  "venue": "Cancers",
  "versions": []
}